Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Korro Bio Inc (KRRO)

Korro Bio Inc (KRRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 409,114
  • Shares Outstanding, K 9,368
  • Annual Sales, $ 0 K
  • Annual Income, $ -81,170 K
  • EBIT $ -108 M
  • EBITDA $ -105 M
  • 60-Month Beta 1.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -2.51
  • Number of Estimates 4
  • High Estimate -2.32
  • Low Estimate -2.68
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.77 +18.77%
on 12/05/24
56.69 -22.97%
on 11/26/24
-3.33 (-7.09%)
since 11/20/24
3-Month
30.72 +42.16%
on 10/04/24
98.00 -55.44%
on 10/16/24
+7.34 (+20.20%)
since 09/20/24
52-Week
30.00 +45.54%
on 06/26/24
98.00 -55.44%
on 10/16/24
-12.14 (-21.75%)
since 12/20/23

Most Recent Stories

More News
Korro Bio, Inc. Receives Approval to Initiate Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro Bio's REWRITE study will assess KRRO-110 for safety and efficacy in treating AATD with participant dosing starting 2025.Quiver AI SummaryKorro Bio, Inc. has announced the approval for its Phase 1/2a...

KRRO : 43.67 (+1.28%)
Korro to Participate in Upcoming Investor Conferences

KRRO : 43.67 (+1.28%)
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

KRRO : 43.67 (+1.28%)
Korro to Present at the Jefferies London Healthcare Conference

KRRO : 43.67 (+1.28%)
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

KRRO : 43.67 (+1.28%)
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

KRRO : 43.67 (+1.28%)
3 Stocks That Could Rise on European Bank Interest Rate Cuts

The European Central Bank cut interest rates for the second time in about three months prior the FOMC's interest rate announcement, European stocks may benefit.

NVDA : 134.70 (+3.08%)
AVGO : 220.79 (+1.13%)
NVO : 85.00 (-17.83%)
KRRO : 43.67 (+1.28%)
IFNNY : 32.7100 (-0.70%)
ASML : 705.68 (-0.64%)
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks

This strategic play will take time to pay off, but it could keep growth going.

NVO : 85.00 (-17.83%)
KRRO : 43.67 (+1.28%)
MRNA : 39.39 (-0.43%)
Target: Fiscal Q2 Earnings Snapshot

Target: Fiscal Q2 Earnings Snapshot

KRRO : 43.67 (+1.28%)
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?

These stocks are coming off a banner month, but what about the road ahead?

KRRO : 43.67 (+1.28%)
GYRE : 11.14 (+4.50%)
IXHL : 1.6800 (-5.88%)

Business Summary

Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.

See More

Key Turning Points

3rd Resistance Point 46.33
2nd Resistance Point 45.48
1st Resistance Point 44.57
Last Price 43.67
1st Support Level 42.81
2nd Support Level 41.96
3rd Support Level 41.05

See More

52-Week High 98.00
Fibonacci 61.8% 72.03
Fibonacci 50% 64.00
Fibonacci 38.2% 55.98
Last Price 43.67
52-Week Low 30.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar